Key result
Percutaneous left atrial appendage occlusion offers a promising alternative to oral anticoagulation for stroke prevention in patients with atrial fibrillation, though further randomized trials are needed.
Why the study?
Prospective controlled trials evaluating left atrial appendage occlusion in patients with AF unsuitable for oral anticoagulation are lacking, and cost-effectiveness has not been assessed in high-risk patients with limited survival.
Does percutaneous left atrial appendage occlusion provide safe and effective stroke prevention in patients with atrial fibrillation who are unsuitable for oral anticoagulation?
Does percutaneous left atrial appendage occlusion provide safe and effective stroke prevention in patients with atrial fibrillation who are unsuitable for oral anticoagulation?
LAA occlusion is a promising alternative for stroke prevention in AF patients unsuitable for oral anticoagulation, but further research is needed to establish long-term outcomes and cost efficacy in high-risk populations.
There are several situations whereby oral anticoagulation may be unsuitable for stroke prevention in patients with atrial fibrillation (AF). Percutaneous left atrial appendage (LAA) occlusion has received much attention in this area. Various devices have already been developed and tested for this purpose. Data from registries and cohort studies have indicated favourable short- and long-term outcomes with LAA occlusion, and several international guidelines recommend its use in AF patients with contraindications to oral anticoagulation. However, prospective controlled trials in this very population are lacking. Furthermore, while modelling studies on cost analyses have suggested that LAA occlusion may be a cost-effective strategy compared with standard medical therapy, these have not been performed in high-risk patients who may have limited survival in the medium to long term. Thus, while LAA occlusion offers promise, there is a strong need for additional research to investigate its exact role, its long-term outcomes and cost efficacy.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2020) conducted a review in Atrial fibrillation. Percutaneous left atrial appendage occlusion vs. Oral anticoagulation was evaluated. Percutaneous left atrial appendage occlusion offers a promising alternative to oral anticoagulation for stroke prevention in patients with atrial fibrillation, though further randomized trials are needed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: